Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$4.78 +0.4%	$4.42	$3.39 ▼ $16.00	$51.77M	0.7	61,108 shs	92,801 shs
FREQ Frequency Therapeutics	$0.30	$0.58	$0.18 ▼ $16.00	$10.94M	0.84	822,537 shs	309,164 shs
IMRX Immuneering	$3.53 +10.7%	$1.79	$1.00 ▼ $3.87	$127.05M	N/A	2.54 million shs	2.75 million shs
IRD Opus Genetics	$0.98 -4.3%	$0.96	$0.65 ▼ $1.75	$58.27M	N/A	525,552 shs	783,289 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	0.00%	+3.02%	+21.01%	-40.32%	-61.67%
FREQ Frequency Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
IMRX Immuneering	0.00%	+37.89%	+110.12%	+132.24%	+175.78%
IRD Opus Genetics	0.00%	+2.79%	-2.66%	-0.53%	+97,659,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	3.1962 of 5 stars	3.5	3.0	0.0	0.0	2.7	1.7	1.3
FREQ Frequency Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	4.0207 of 5 stars	3.3	4.0	0.0	0.0	4.1	5.0	0.6
IRD Opus Genetics	1.8084 of 5 stars	3.5	0.0	0.0	0.0	2.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	3.00	Buy	$30.00	527.62% Upside
FREQ Frequency Therapeutics	0.00	N/A	N/A	N/A
IMRX Immuneering	2.60	Moderate Buy	$13.25	275.35% Upside
IRD Opus Genetics	3.00	Buy	$7.33	650.90% Upside

Current Analyst Ratings Breakdown

Latest FREQ, AVTX, IRD, and IMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/7/2025	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
5/6/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/11/2025	IRD Opus Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
4/10/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/1/2025	IRD Opus Genetics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$440K	117.65	N/A	N/A	$12.80 per share	0.37
FREQ Frequency Therapeutics	$14.07M	0.78	N/A	N/A	$1.96 per share	0.15
IMRX Immuneering	$320K	397.01	N/A	N/A	$1.33 per share	2.65
IRD Opus Genetics	$13.65M	4.27	N/A	N/A	$0.21 per share	4.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	111.00%	58.88%	8/11/2025 (Estimated)
FREQ Frequency Therapeutics	-$81.58M	-$1.89	N/A	N/A	N/A	N/A	-107.67%	-61.40%	N/A
IMRX Immuneering	-$61.04M	-$1.96	N/A	N/A	N/A	N/A	-119.22%	-99.22%	8/5/2025 (Estimated)
IRD Opus Genetics	-$57.53M	-$2.10	N/A	N/A	N/A	-429.42%	-283.28%	-144.32%	8/12/2025 (Estimated)

Latest FREQ, AVTX, IRD, and IMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IRD Opus Genetics	-$0.34	-$0.32	+$0.02	-$0.24	$4.00 million	$4.30 million
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A
3/31/2025	Q4 2024	IRD Opus Genetics	-$0.34	-$1.27	-$0.93	-$1.27	$11.10 million	$3.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
FREQ Frequency Therapeutics	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	22.61	22.61
FREQ Frequency Therapeutics	N/A	5.81	5.81
IMRX Immuneering	N/A	7.48	7.48
IRD Opus Genetics	N/A	1.98	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
FREQ Frequency Therapeutics	13.18%
IMRX Immuneering	67.65%
IRD Opus Genetics	14.97%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	0.25%
FREQ Frequency Therapeutics	16.80%
IMRX Immuneering	22.90%
IRD Opus Genetics	6.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.80 million	Not Optionable
FREQ Frequency Therapeutics	46	36.52 million	30.39 million	Not Optionable
IMRX Immuneering	60	35.99 million	27.75 million	Not Optionable
IRD Opus Genetics	14	59.66 million	55.72 million	N/A

FREQ, AVTX, IRD, and IMRX Headlines

Recent News About These Companies

Opus Genetics (NASDAQ:IRD) Earns "Buy" Rating from HC Wainwright

June 29 at 2:01 AM | americanbankingnews.com

Opus Genetics (NASDAQ:IRD) Cut to "Sell" at Wall Street Zen

June 28 at 3:49 AM | americanbankingnews.com

Opus Genetics (NASDAQ:IRD) Stock Rating Lowered by Wall Street Zen

June 28 at 3:15 AM | marketbeat.com

HC Wainwright Reiterates Buy Rating for Opus Genetics (NASDAQ:IRD)

June 27 at 8:07 AM | marketbeat.com

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

June 26, 2025 | globenewswire.com

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

June 23, 2025 | globenewswire.com

Phentolamine Eye Drops Improve Night Driving Post-Refractive Surgery in Phase 3 trial

June 20, 2025 | medicaldialogues.inM

Opus Genetics (NASDAQ:IRD) Trading 1% Higher - What's Next?

June 6, 2025 | marketbeat.com

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under ...

June 4, 2025 | seekingalpha.com

IRD Opus Genetics, Inc.

June 3, 2025 | seekingalpha.com

Opus Genetics releases topline results from LYNX-2 evaluating phentolamine ophthalmic solution 0.75%

June 2, 2025 | ophthalmologytimes.comO

Opus Genetics Shares Rise After Positive Trial Results for Eye Treatment

June 2, 2025 | marketwatch.com

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

June 2, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/02/3091780/0/en/opus-genetics-announces-lynx-2-phase-3-trial-met-its-primary-endpoint-for-phentolamine-ophthalmic-solution-0-75-in-keratorefractive-patients-with-visual-disturbances-under-mesopic-.html$

Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 18, 2025 | finance.yahoo.com

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates

May 15, 2025 | zacks.com

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 15, 2025 | globenewswire.com

Opus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025

May 13, 2025 | nasdaq.com

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 12, 2025 | globenewswire.com

RMAT designation for Opus’ OPGx-LCA5 gene therapy candidate

May 7, 2025 | thepharmaletter.comT

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 6, 2025 | globenewswire.com

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

May 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Microsoft Stock Holds Steady as AI Drives Workforce Shift
By Chris Markoch | June 23, 2025
View Microsoft Stock Holds Steady as AI Drives Workforce Shift
Regional Bank Buybacks: 5 Institutions Making Big Moves
By Leo Miller | June 24, 2025
View Regional Bank Buybacks: 5 Institutions Making Big Moves

FREQ, AVTX, IRD, and IMRX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$4.78 +0.02 (+0.42%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.60 +4.82 (+100.84%)

As of 04:00 AM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Frequency Therapeutics NASDAQ:FREQ

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Immuneering NASDAQ:IMRX

$3.53 +0.34 (+10.66%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.62 +0.09 (+2.41%)

As of 05:00 AM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Opus Genetics NASDAQ:IRD

$0.98 -0.04 (-4.25%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.94 -0.04 (-3.95%)

As of 04:58 AM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time